You are here

  • Home
  • Archive
  • Volume 68, Issue 6
  • Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Article info

Article menu

Download PDFPDF

XML
Hepatology
Original article
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Authors

  • Roser Pinyol BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Robert Montal BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Laia Bassaganyas BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Daniela Sia Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Tadatoshi Takayama Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Gar-Yang Chau Department of surgery, Taipei Veterans General Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Vincenzo Mazzaferro Hepatology and Liver Transplantation Unit, Department of Surgery, University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy PubMed articlesGoogle scholar articles
  • Sasan Roayaie Liver Cancer Program, White Plains Hospital, Montefiore Health, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Han Chu Lee Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea PubMed articlesGoogle scholar articles
  • Norihiro Kokudo Department of surgery, University of Tokyo, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Zhongyang Zhang Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Sara Torrecilla BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Agrin Moeini BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Leonardo Rodriguez-Carunchio BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Edward Gane New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand PubMed articlesGoogle scholar articles
  • Chris Verslype Department of Hepatology, University Hospital Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Adina Emilia Croitoru Departament of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania PubMed articlesGoogle scholar articles
  • Umberto Cillo Unità Operativa di Chirurgia Epatobiliare e Trapianto Epatico, Azienda Ospedaliera Università di Padova, Padova, Italy PubMed articlesGoogle scholar articles
  • Manuel de la Mata Unit of Hepatology and Liver Transplantation, CIBERehd, IMIBIC, University Hospital Reina Sofia, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Luigi Lupo Sezione Chirurgia Generale e Trapianti di Fegato, Policlinico di Bari, Bari, Italy PubMed articlesGoogle scholar articles
  • Simone Strasser AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital–University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Joong-Won Park Department of Cancer Control and Population Health, National Cancer Center, Goyang, South Korea PubMed articlesGoogle scholar articles
  • Jordi Camps Gastrointestinal and Pancreatic Oncology Group, IDIBAPS–Hospital Clínic, CIBERehd, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Manel Solé BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Swan N Thung Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Augusto Villanueva Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Carol Pena Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA PubMed articlesGoogle scholar articles
  • Gerold Meinhardt Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA PubMed articlesGoogle scholar articles
  • Jordi Bruix BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Josep M Llovet BCLC Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Josep M Llovet, Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), IDIBAPS-Hospital Clinic, Barcelona, 08036 Catalonia, Spain; jmllovet{at}clinic.cat
View Full Text

Citation

Pinyol R, Montal R, Bassaganyas L, et al
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Gut 2019;68:1065-1075.

Publication history

  • Received April 5, 2018
  • Revised July 16, 2018
  • Accepted July 16, 2018
  • First published October 2, 2018.
Online issue publication 
March 28, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.